Interleukin strikes deals for genetic tests
This article was originally published in Clinica
Executive Summary
In a move to bulk up its portfolio, Interleukin Genetics, the Waltham, Massachusetts-based developer of genetic tests for the personalised health market, is teaming up with healthcare services provider Geisinger Health System to develop products for predicting an individual's genetic predisposition to weight loss success. The two companies will carry out a case-control retrospective study involving the analysis of DNA to better understand the genetic links to obesity. The study will focus exclusively on variations of perilipin, interleukin 1 and a select number of other genes.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.